Insights
January 09, 2018 –
John L. Fox, MD, discusses current coverage considerations surrounding the use of PARP inhibitors for patients with advanced ovarian cancer.
January 09, 2018 –
John L. Fox, MD, explains how collaboration between payers and gynecologic oncologists, as well as other specialists, can be valuable in improving the management of ovarian cancer.
January 02, 2018 –
John L. Fox, MD, provides an overview of current treatment guidelines in ovarian cancer and explains how they influence coverage decisions by payers.
January 02, 2018 –
John L. Fox, MD, remarks on unmet needs in the detection and management of ovarian cancer.
December 27, 2017 –
Robert L. Coleman, MD, discusses nuances in PARP inhibitor patient selection and explains how the research findings with these new drugs continues to move the ovarian cancer field forward.
December 19, 2017 –
Robert L. Coleman, MD, offers insight regarding the current knowledge with predictive markers in ovarian cancer.
December 19, 2017 –
Robert L. Coleman, MD, reviews evidence with bevacizumab in the frontline setting of ovarian cancer and discusses how the availability of newer options impacts maintenance decisions.
December 12, 2017 –
Robert L. Coleman, MD, offers insight regarding the findings from ARIEL3, with rucaparib in the switch maintenance setting of ovarian cancer.
December 12, 2017 –
Robert L. Coleman, MD, examines efficacy and safety data from NOVA with niraparib, and Study 19 and SOLO-2 with olaparib in ovarian cancer.
December 05, 2017 –
Robert L. Coleman, MD, discusses the risk of recurrence in ovarian cancer and explains the concept of switch maintenance.
